

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

33. (Canceled).

34. (Currently Amended). A ~~pharmaceutical~~ composition comprising
at least one immunogenic peptide consisting of 15 amino acids, wherein
the peptide has the formula: L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID NO: 2)

~~R₁-R₂-R₃-R₄-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-R₅-R₆~~ [SEQ ID NO: 1]

wherein:

~~— R₁ is leucine (L); glutamine (Q), tyrosine (Y) or aspartate (D);~~

~~— R₂ is glutamate (E); aspartate (D) or asparagine (N);~~

~~— R₃ is glutamine (Q) aspartate (D) or serine (S);~~

~~— R₄ is isoleucine (I);~~

~~— X₁, X₆, and X₉ are independently selected from tryptophan (W),~~

~~phenylalanine (F), and tyrosine (Y);~~

~~— X₂ is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);~~

~~— X₃ is asparagine (N);~~

~~— X₄ is methionine (M) or leucine (L);~~

~~— X₅ is threonine (T);~~

~~— X₇ is methionine (M), isoleucine (I), glutamine (Q), or leucine (L); and~~

~~— X₈ is glutamine (Q) or glutamate (E); and~~

~~— R₅ is glutamate (E) or aspartate (D);~~

~~— R₆ is lysine (K), glutamine (Q) or arginine (R); or~~

a pharmaceutically acceptable salt of the immunogenic peptide;

~~wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K [SEQ ID NO: 1]; and~~

a pharmaceutically acceptable vehicle.

35. (Currently Amended). A pharmaceutical composition comprising
at least one immunogenic peptide consisting of up to 31 amino acids,
wherein the peptide has the formula: C-T-T-A-V-P-W-N-A-S-W-S-N-K-S-L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID NO: 4)

~~R₇-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁ [SEQ ID NO: 1]~~

wherein:

~~_____ R₇ is an amino acid chain of up to 20 amino acids other than aromatic amino acids;~~

~~_____ X₁, X₆, and X₉ are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);~~

~~_____ X₂ is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);~~

~~_____ X₃ is asparagine (N);~~

~~_____ X₄ is methionine (M) or leucine (L);~~

~~_____ X₅ is threonine (T);~~

~~_____ X₇ is methionine (M), isoleucine (I), glutamine (Q), or leucine (L);~~

~~_____ X₈ is glutamine (Q) or glutamate (E);~~

~~_____ X₁₀ is aspartate (D) or glutamate (E)~~

~~_____ X₁₁ is lysine (K) glutamine (Q) or arginine (R); or~~

a pharmaceutically acceptable salt of the immunogenic peptide;

~~wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (CBD1) [SEQ ID NO: 1]; and~~

a pharmaceutically acceptable vehicle.

36. (Canceled).

37. (Canceled).

38. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~36~~ 34 or claim 35, wherein the peptide is glycosylated or phosphorylated.

39. (Canceled).

40. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~36~~ 34 or claim 35, wherein the pharmaceutically acceptable salt is an organic or inorganic acid salt formed with free amino groups of the peptide.

41. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~39~~ 34 or claim 35, wherein acid salt is a salt of phosphoric acid, hydrochloric acid, acetic acid, or oxalic acid.

42. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~40~~ 41, wherein the pharmaceutically acceptable vehicle comprises saline, dextrose, glycerol, water, ethanol, or combinations thereof.

43. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~44~~ 42, which comprises an adjuvant.

44. (Currently Amended). The ~~pharmaceutical~~ composition as claimed in claim ~~40~~ 43, wherein the composition is encapsulated in a polymer, liposome, or micelle.

45 - 57. (Canceled).